BioCentury | Sep 8, 2014
Company News

Biolipox, Boehringer Ingelheim deal

...chronic inflammatory pain conditions. Boehringer had rights to the program under a 2005 deal with Biolipox AB...
...no future commitments to the project (see BioCentury, Nov. 21, 2005 & Dec. 3, 2007). Biolipox AB...
BioCentury | Jun 7, 2010
Strategy

J&J's Pulmonary Push

...in Orexo's expertise in arachidonic acid metabolism, which it gained in its 2007 acquisition of Biolipox AB...
BioCentury | Sep 15, 2008
Company News

Orexo, Boehringer Ingelheim deal

...compounds are in preclinical testing. Orexo, which gained the compounds in its November acquisition of Biolipox AB...
BioCentury | Aug 25, 2008
Company News

Inflazyme inflammation, neurology news

...company exited the pharmaceutical business. It had sold its remaining compounds to Biolipox AB last year. Biolipox...
BioCentury | Mar 24, 2008
Clinical News

OX-NLA: Phase II data

...an episode of rhinitis was triggered. Orexo acquired the nasal spray through its acquisition of Biolipox AB...
BioCentury | Feb 14, 2008
Distillery Therapeutics

This Week in Therapeutics

...Orexo AB plans to begin Phase I testing of OX-2477, a 15-lipoxygenase inhibitor acquired from Biolipox AB...
...Sci. USA; published online Jan. 9, 2008; doi:10.1073/pnas.0710127105 Contact: Hans-Erik Claesson, Biolipox AB, Solna, Sweden; e-mail: hans-erik.claesson@biolipox.com BC...
BioCentury | Dec 3, 2007
Company News

Biolipox, Inflazyme, Orexo deal

...its Prodaptin tethering technology (see BioCentury, Oct. 1). ORX completed its previously announced acquisition of Biolipox...
...ORX's close of SEK55.75 on Nov. 22, the last trading day before the deal closed. Biolipox AB...
BioCentury | Nov 19, 2007
Company News

Biolipox, Orexo deal

...an inhibitor of prostaglandin E synthase-2 (PGES-2) that is in preclinical testing for inflammatory pain. Biolipox AB...
...Biolipox (see BioCentury, Oct. 22). Instead of receiving 8.6 million shares of ORX up front, Biolipox...
BioCentury | Oct 22, 2007
Finance

Ebb & Flow

...share. Orexo (SSE:ORX) lost SEK10.75 (12%) to SEK80 last Monday after it proposed to acquire Biolipox...
BioCentury | Oct 22, 2007
Strategy

Moving on up

...up Moving on up Based on last Friday's close, the newco combining Orexo (SSE:ORX) and Biolipox...
...valued above $100 million. $M Company 10/19 mcap Biovitrum SEK3,832.3 ($596.7) Active Biotech SEK3,311.0 ($515.5) Orexo-Biolipox...
Items per page:
1 - 10 of 47
BioCentury | Sep 8, 2014
Company News

Biolipox, Boehringer Ingelheim deal

...chronic inflammatory pain conditions. Boehringer had rights to the program under a 2005 deal with Biolipox AB...
...no future commitments to the project (see BioCentury, Nov. 21, 2005 & Dec. 3, 2007). Biolipox AB...
BioCentury | Jun 7, 2010
Strategy

J&J's Pulmonary Push

...in Orexo's expertise in arachidonic acid metabolism, which it gained in its 2007 acquisition of Biolipox AB...
BioCentury | Sep 15, 2008
Company News

Orexo, Boehringer Ingelheim deal

...compounds are in preclinical testing. Orexo, which gained the compounds in its November acquisition of Biolipox AB...
BioCentury | Aug 25, 2008
Company News

Inflazyme inflammation, neurology news

...company exited the pharmaceutical business. It had sold its remaining compounds to Biolipox AB last year. Biolipox...
BioCentury | Mar 24, 2008
Clinical News

OX-NLA: Phase II data

...an episode of rhinitis was triggered. Orexo acquired the nasal spray through its acquisition of Biolipox AB...
BioCentury | Feb 14, 2008
Distillery Therapeutics

This Week in Therapeutics

...Orexo AB plans to begin Phase I testing of OX-2477, a 15-lipoxygenase inhibitor acquired from Biolipox AB...
...Sci. USA; published online Jan. 9, 2008; doi:10.1073/pnas.0710127105 Contact: Hans-Erik Claesson, Biolipox AB, Solna, Sweden; e-mail: hans-erik.claesson@biolipox.com BC...
BioCentury | Dec 3, 2007
Company News

Biolipox, Inflazyme, Orexo deal

...its Prodaptin tethering technology (see BioCentury, Oct. 1). ORX completed its previously announced acquisition of Biolipox...
...ORX's close of SEK55.75 on Nov. 22, the last trading day before the deal closed. Biolipox AB...
BioCentury | Nov 19, 2007
Company News

Biolipox, Orexo deal

...an inhibitor of prostaglandin E synthase-2 (PGES-2) that is in preclinical testing for inflammatory pain. Biolipox AB...
...Biolipox (see BioCentury, Oct. 22). Instead of receiving 8.6 million shares of ORX up front, Biolipox...
BioCentury | Oct 22, 2007
Finance

Ebb & Flow

...share. Orexo (SSE:ORX) lost SEK10.75 (12%) to SEK80 last Monday after it proposed to acquire Biolipox...
BioCentury | Oct 22, 2007
Strategy

Moving on up

...up Moving on up Based on last Friday's close, the newco combining Orexo (SSE:ORX) and Biolipox...
...valued above $100 million. $M Company 10/19 mcap Biovitrum SEK3,832.3 ($596.7) Active Biotech SEK3,311.0 ($515.5) Orexo-Biolipox...
Items per page:
1 - 10 of 47